Post-Finasteride Syndrome: A Review of the Clinical Evidence
Medically reviewed by [Reviewer Name, MD] | Last reviewed: August 2026 | Editorial policy | Full PFS guide
This page summarizes the published clinical evidence base specifically for Post-Finasteride Syndrome (PFS), the constellation of persistent sexual, neuropsychological, and physical adverse effects reported by a subset of men after stopping finasteride.
Key Evidence Landmarks
| Year | Publication/Event | Key contribution |
|---|---|---|
| 2011 | Irwig MS, Kolukula S. case series (J Sex Med) | Structured interviews with 71 otherwise healthy men whose new sexual side effects persisted for at least 3 months after stopping finasteride |
| 2012 | FDA Propecia/Proscar label update | Official regulatory acknowledgment that sexual adverse effects may persist after discontinuation |
| 2014 | Melcangi RC et al. | Documented reduced neuroactive steroid levels (including allopregnanolone and 5α-androstane-3α,17β-diol) in PFS patients vs. controls |
| 2017 | Melcangi RC et al. J Steroid Biochem | Further neuroactive steroid profiling + psychiatric symptom documentation in Italian PFS cohort |
| 2025 | EMA Article 31 review | Confirmed suicidal ideation as a side effect of finasteride tablets |
Evidence Quality Assessment
- Existence of PFS: Well-supported by case series, registry data, FDA and EMA regulatory actions, and biologically plausible mechanisms. Evidence level: moderate-high for existence of the phenomenon.
- Frequency: Not established. No prospective population-level incidence study has been completed. Evidence level: insufficient.
- Mechanism: Multiple proposed (neurosteroid, epigenetic AR, peripheral neurological); none conclusively established in humans. Evidence level: hypothesis-generating, not confirmatory.
- Treatment: No RCT-supported treatment exists. Evidence level: insufficient.
Full clinical guide: Post-Finasteride Syndrome: Symptoms, Evidence, and Research
Sources
- Irwig MS, Kolukula S. “Persistent sexual side effects of finasteride for male pattern hair loss.” J Sex Med. 2011;8(6):1747-1753.
- Melcangi RC, et al. “Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients.” J Sex Med. 2013;10(10):2598-2603.
- European Medicines Agency. PRAC recommendations on signals. November 2019.